Statin Prescription Patterns and Associated Factors Among Patients with Type 2 Diabetes Mellitus Attending Diabetic Clinic at Muhimbili National Hospital, Dar es Salaam, Tanzania

References

• King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21(9):1414–1431. doi:10.2337/diacare.21.9.1414
   PubMed Web of Science ®Google Scholar
• Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: have all risk factors the same strength? World J Diabetes. 2014;5(4):444. doi:10.4239/wjd.v5.i4.444
   PubMedGoogle Scholar
• Morrish N, Wang S-L, Stevens L, Fuller J, Keen H, Group WMS. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44(2):S14. doi:10.1007/PL00002934
   Web of Science ®Google Scholar
• Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590. doi:10.1016/S0140-6736(12)60367-5
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278. doi:10.1016/S0140-6736(05)67394-1
   PubMed Web of Science ®Google Scholar
• Pyörälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614–620. doi:10.2337/diacare.20.4.614
   PubMed Web of Science ®Google Scholar
• Armitage J, Collins R. Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials. Heart. 2000;84(4):357–360. doi:10.1136/heart.84.4.357
   Web of Science ®Google Scholar
• Shepherd J, Barter P, Carmena R, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating To New Targets (TNT) study. Diabetes Care. 2006;29:1220–1226. doi:10.2337/dc05-2465
   PubMed Web of Science ®Google Scholar
• Sever P, Poulter N, Chang C-L, et al. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT): testing C-Reactive protein at baseline and on-treatment as an independent predictor of cardiovascular outcomes. Am Coll Cardiol. 2013;8(62):8–20. doi:10.1016/j.jacc.2013.02.098
   Web of Science ®Google Scholar
• Knopp RH, D’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care. 2006;29:1478–1485. doi:10.2337/dc05-2415
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–696. doi:10.1016/S0140-6736(04)16895-5
   PubMed Web of Science ®Google Scholar
• Cefalu WT, Berg EG, Saraco M, et al. American Diabetes Association: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl.1):S15–S33. doi:10.2337/dc21-S002
   Web of Science ®Google Scholar
• Weng TC, Yang YHK, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35(2):139–151. doi:10.1111/j.1365-2710.2009.01085.x
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681. doi:10.1016/S0140-6736(10)61350-5
   PubMed Web of Science ®Google Scholar
• Wilson PWF, Polonsky TS, Miedema MD, Khera A, Kosinski AS, Kuvin JT. Correction to: systematic Review for the 2018AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1144–e1161. doi:10.1161/CIR.0000000000000700
   Web of Science ®Google Scholar
• Morieri ML, Perrone V, Veronesi C, et al. Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets’ attainment in subjects with and without type 2 diabetes. Cardiovasc Diabetol. 2021;20:144. doi:10.1186/s12933-021-01338-y
   PubMed Web of Science ®Google Scholar
• Ray KK, Molemans B, Schoonen WM, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DAVINCI study. Eur J Prev Cardiol. 2021;28:1279–1289. doi:10.1093/eurjpc/zwaa047
   PubMed Web of Science ®Google Scholar
• Morieri ML, Avogaro A, Fadini GP; the DARWIN-T2D Network of the Italian Diabetes Society. Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics. Cardiovasc Diabetol. 2020;19:190. doi:10.1186/s12933-020-01164-8
   Web of Science ®Google Scholar
• Roman WP, Martin HD, Sauli E. Cardiovascular diseases in Tanzania: the burden of modifiable and intermediate risk factors. J Xiangya Med. 2019;1–13. doi:10.21037/jxym.2019.07.03
   Google Scholar
• Mboera L, Kishamawe C, Rumisha SF, Chiduo MG, Kimario E. Patterns and trends of hospital mortality due to noncommunicable diseases and injuries in Tanzania: a 10- year retrospective analysis. Available from: https://orcid.org/0000-0001-5746-3776. Accessed February 15, 2022.
   Google Scholar
• Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013;40(1):195–211. doi:10.1016/j.pop.2012.11.003
   PubMed Web of Science ®Google Scholar
• Arya R, Antonisamy B, Kumar S. Sample size estimation in prevalence studies. Indian J Pediatr. 2012;79(11):1482–1488. doi:10.1007/s12098-012-0763-3
   PubMed Web of Science ®Google Scholar
• Gupta R, Lodha S, Sharma KK, et al. Evaluation of statin prescriptions in type 2 diabetes: india Heart Watch-2. BMJ Open Diabetes Res Care. 2016;4(1):e000275. doi:10.1136/bmjdrc-2016-000275
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–239. doi:10.1161/01.CIR.0000133317.49796.0E
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25Pt B):2889–2934. doi:10.1016/j.jacc.2013.11.002
   PubMed Web of Science ®Google Scholar
• Jellinger PS, Handelsman Y, Rosenblit PD, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23(Suppl 2):1–87. doi:10.4158/EP171764.APPGL
   PubMed Web of Science ®Google Scholar
• Tanzania Ministry of Health. Tanzania Demorgraphic and Health Survey Indicator Survey (TDHS-MIS) 2015–2016. Dar Es Salaam, Tanzania, Rockville, Maryland, USA MoHCDGEC, MoH, NBS, OCGS, ICF. Available from: https://dhsprogram.com/pubs/pdf/fr321/fr321.pdf. Accessed October 23, 2021.
   Google Scholar
• Williams JS, Brown SM, Conlin PR. Videos in clinical medicine. blood-pressure measurement. N Engl J Med. 2009;360(5):e6. doi:10.1056/NEJMvcm0800157
   Web of Science ®Google Scholar
• James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520. doi:10.1001/jama.2013.284427
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Glycemic targets: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Supplement 1):s61–s70. doi:10.2337/dc19-S006
   PubMed Web of Science ®Google Scholar
• Akaike information criterion. Available from: https://www.sciencedirect.com/topics/social-sciences/akaike-information-criterion. Accessed January 05, 2022.
   Google Scholar
• Mwita JC, Godman B, Esterhuizen TM. Statin prescription among patients with type 2 diabetes in Botswana: findings and implications. BMC Endocr Disord. 2020;20(1):36. doi:10.1186/s12902-020-0516-7
   PubMed Web of Science ®Google Scholar
• Demoz GT, Wahdey S, Kasahun GG, et al. Prescribing pattern of statins for primary prevention of cardiovascular diseases in patients with type 2 diabetes: insights from Ethiopia. BMC Res Notes. 2019;12(1):386. doi:10.1186/s13104-019-4423-9
   Web of Science ®Google Scholar
• Berthold HK, Gouni-Berthold I, Böhm M, Krone W, Bestehorn KP. Patterns and predictors of statin prescription in patients with type 2 diabetes. Cardiovasc Diabetol. 2009;8(25):1–12. doi:10.1186/1475-2840-8-25
   Web of Science ®Google Scholar
• IDF Diabetes Atlas 2019. International diabetes federation; 2019. Available from: http://www.idf.org/about-diabetes/facts-figures. Accessed October 23, 2021.
   Google Scholar
• Sarfo FS, Ovbiagele B. Prevalence and predictors of statin utilization among patient populations at high vascular risk in Ghana. J Neurol Sci. 2020;414:116838. doi:10.1016/j.jns.2020.116838
   PubMed Web of Science ®Google Scholar
• Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim AS. Association of industry payments to physicians with the prescribing of brand-name statins in Massachusetts. JAMA Intern Med. 2016;176(6):763–768. doi:10.1001/jamainternmed.2016.1709
   PubMed Web of Science ®Google Scholar
• Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction? Expert Opin Pharmacother. 2015;16(10):1449–1461. doi:10.1517/14656566.2015.1053464
   PubMed Web of Science ®Google Scholar
• Singh BM, Lamichhane HK, Srivatsa SS, et al. Role of statins in the primary prevention of atherosclerotic cardiovascular disease and mortality in the population with mean cholesterol in the near-optimal to borderline high range: a systematic review and meta-analysis. Adv Prev Med. 2020;2020:6617905. doi:10.1155/2020/6617905
   Google Scholar
• Wu J, Zhu S, Yao GL, Mohammed MA, Marshall T. Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a National Retrospective Cohort Study. PLoS One. 2013;8(7):e67611. doi:10.1371/journal.pone.0067611
   Web of Science ®Google Scholar
• Norris P, Horsburgh S, Becket G, et al. Equity in statin use in New Zealand. J Prim Health Care. 2014;6(1):17–22. doi:10.1071/HC14017
   Google Scholar
• Kitzmiller JP, Foraker RE, Rose KM. Lipid-lowering pharmacotherapy and socioeconomic status: atherosclerosis risk in communities (ARIC) surveillance study. BMC Public Health. 2013;13:488. doi:10.1186/1471-2458-13-488
   Web of Science ®Google Scholar
• King DE, Mainous AG, Egan BM, Player M, Geesey ME. Use of statins and blood pressure. Am J Hypertens. 2007;20(9):937–941. doi:10.1016/j.amjhyper.2007.03.018
   Web of Science ®Google Scholar
• D’Agostino RB, Kannel WB, Stepanians MN, D’Agostino LC. Efficacy and tolerability of lovastatin in hypercholesterolemia in patients with systemic hypertension. Am J Cardiol. 1993;71(1):82–87. doi:10.1016/0002-9149(93)90715-o
   Web of Science ®Google Scholar
• Lielith V. Type 2 diabetes mellitus in a dutch region: epidemiology and shared care. Available from: https://pure.rug.nl/ws/portalfiles/portal/66113685/L.Ubink_Veltmaat.pdf. Accessed October 23, 2021.
   Google Scholar
• Neutel CI, Morrison H, Campbell NRC, de Groh M. Statin use in Canadians: trends, determinants and persistence. Can J Public Heal. 2007;98(5):412–416. doi:10.1007/BF03405430
   Web of Science ®Google Scholar
• Savoie I, Kazanjian A. Utilization of lipid-lowering drugs in men and women. a reflection of the research evidence? J Clin Epidemiol. 2002;55(1):95–101. doi:10.1016/s0895-4356(01)00436-x
   Web of Science ®Google Scholar
• chulz KF, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials Br Med J. 2010;340:c332. doi:10.1136/bmj.c332. Creative Commons.
   Web of Science ®Google Scholar